Access to medicine is a vital issue at the crossroads of global health issue, corporate responsibility, and ESG investing. Join us as we unpack barriers to equitable access, explore how pharmaceutical companies and ESG-focused investors are addressing these challenges, the emergence of patient reach is as a measure of progress, and how improvements in reporting can align access initiatives with business models to drive both sustainable growth and social impact.

Birgit Lundem Jakobsen, ESG Specialist at PGIM, hosts this discussion with Bram Wagner, Investor Engagement Lead for the Access to Medicine Foundation, and Hank Balbirer, CFA, U.S. Investment Grade Senior Credit Research Analyst at PGIM.

Recorded on November 5, 2025.